Skip to main content
SpringerLink
Log in

Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

The no-reflow phenomenon occurs when an epicardial coronary artery is reopened following myocardial infarction, but portions of the intramural microvasculature fail to reperfuse. One potential mechanism for this is the presence of fibrin tactoids. In addition, some recent studies have suggested that dabigatran treatment may be associated with increased incidence of myocardial infarction. Our aim was to investigate the effect on myocardial infarct size and no-reflow in an acute model of ischemia/reperfusion. Anesthetized, open-chest rabbits were randomly assigned to receive dabigatran (Dab, 0.5 mg/kg bolus + infusion, 0.15 mg/kg/h, IV, n = 11) or vehicle (Veh, n = 11) 15 m before a 30-m coronary artery occlusion and during 2.5 h of the 3 h reperfusion procedure. At the end of the reperfusion period, infarct size (% risk zone) and no-reflow defect were measured. The ischemic risk zone (% of left ventricle) was similar in groups, 24 % in Dab and 25 % in Veh. Necrosis was neither reduced nor increased by Dab treatment; expressed as a percentage of the risk region, infarct size was 30 ± 4 % in Dab and 28 ± 5 % in Veh, p = 0.76. The extent of no-reflow was comparable, expressed either as a percent of the risk region (19 ± 3 %, Dab and 18 ± 3 %, Veh) or as a percent of the necrotic zone (67 ± 8 % Dab and 65 ± 10 % Veh). Dab treatment had no effect on heart rate or blood pressure. Dabigatran treatment did not prevent or ameliorate the no-reflow phenomenon, suggesting that fibrin does not play a major role in the development of microvascular obstruction. Dabigatran did not exacerbate myocardial infarct size.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bolognese L, Falsini G, Liistro F, Angioli P, Ducci K (2005) Epicardial and microvascular reperfusion with primary percutaneous coronary intervention. Ital Heart J 6:447–452

    PubMed  Google Scholar 

  2. Brosh D, Assali AR, Mager A, Porter A, Hasdai D, Teplitsky I, Rechavia E, Fuchs S, Battler A, Kornowski R (2007) Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on 6-month mortality. Am J Cardiol 99:442–445

    Article  PubMed  Google Scholar 

  3. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, Mukawa H, Matsui H, Toki Y, Ito T, Hayakawa T (2000) Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 36:1202–1209

    Article  CAS  PubMed  Google Scholar 

  4. Zhang ZG, Chopp M, Goussev A, Lu D, Morris D, Tsang W, Powers C, Ho KL (1999) Cerebral microvascular obstruction by fibrin is associated with upregulation of PAI-1 acutely after onset of focal embolic ischemia in rats. J Neurosci 19:10898–10907

    CAS  PubMed  Google Scholar 

  5. Kloner RA, Ganote CE, Jennings RB (1974) The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 54:1496–1508

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Reffelmann T, Kloner RA (2002) The “no-reflow” phenomenon: basic science and clinical correlates. Heart 87:162–168

    Article  PubMed Central  PubMed  Google Scholar 

  7. Mak KH (2012) Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open 2(5):e001592. doi:10.1136/bmjopen-2012-001592

    Article  PubMed Central  PubMed  Google Scholar 

  8. Uchino K, Hernandez AV (2012) Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 172:397–402

    Article  CAS  PubMed  Google Scholar 

  9. Hale SL, Kloner RA (1997) Myocardial temperature in acute myocardial infarction: protection with mild regional hypothermia. Am J Physiol 273:H220–H227

    CAS  PubMed  Google Scholar 

  10. Hale SL, Kloner RA (2010) Cardioprotection with adenosine-regulating agent, GP531: effects on no-reflow, infarct size, and blood flow following ischemia/reperfusion in the rabbit. J Cardiovasc Pharmacol Ther 15:60–67

    Article  CAS  PubMed  Google Scholar 

  11. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N (2007) Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. J Thromb Haemost 5:1237–1242

    Article  CAS  PubMed  Google Scholar 

  12. Jaffe R, Charron T, Puley G, Dick A, Strauss BH (2008) Microvascular obstruction and the no-reflow phenomenon after percutaneous coronary intervention. Circulation 117:3152–3156

    Article  PubMed  Google Scholar 

  13. Nanobashvili J, Neumayer C, Fuegl A, Blumer R, Prager M, Sporn E, Polterauer P, Malinski T, Huk I (2003) Development of ‘no-reflow’ phenomenon in ischemia/reperfusion injury: failure of active vasomotility and not simply passive vasoconstriction. Eur Surg Res 35:417–424

    Article  CAS  PubMed  Google Scholar 

  14. Vrints CJ (2009) Pathophysiology of the no-reflow phenomenon. Acute Card Care 11:69–76

    Article  PubMed  Google Scholar 

  15. Widgerow AD (2014) Ischemia-reperfusion injury: influencing the microcirculatory and cellular environment. Ann Plast Surg 72:253–260. doi:10.1097/SAP.0b013e31825c089c

    Article  CAS  PubMed  Google Scholar 

  16. Kloner RA, Ganote CE, Jennings RB, Reimer KA (1975) Demonstration of the “no-reflow” phenomenon in the dog heart after temporary ischemia. Recent Adv Stud Cardiac Struct Metab 10:463–474

    CAS  PubMed  Google Scholar 

  17. Wohrle J, Merkle N, Kunze M, Cristea E, Mehran R, Rottbauer W, Stone GW (2012) Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy. Catheter Cardiovasc Interv 79:1083–1089

    Article  PubMed  Google Scholar 

  18. Gerotziafas GT, Galea V, Mbemba E, Sassi M, Roman MP, Khaterchi A, van DP, Japcowitz M, Lotz JP, Bernaudin JF, Fareed J, Hatmi M, Elalamy I (2012) Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3. Curr Vasc Pharmacol [Epub ahead of print]

  19. Macchi L, Moussa WB, Guillou S, Tamareille S, Lamon D, Prunier D, Prunier F (2014) The synthetic pentasaccharide fondaparinux attenuates myocardial ischemia-reperfusion injury in rats via STAT-3. Shock 41:166–171

    Article  CAS  PubMed  Google Scholar 

  20. Chong AJ, Pohlman TH, Hampton CR, Shimamoto A, Mackman N, Verrier ED (2003) Tissue factor and thrombin mediate myocardial ischemia-reperfusion injury. Ann Thorac Surg 75:S649–S655

    Article  PubMed  Google Scholar 

  21. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C (2012) Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol 31:330–339

    CAS  PubMed  Google Scholar 

  22. Artang R, Rome E, Nielsen JD, Vidaillet HJ (2013) Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol 112:1973–1979

    Article  CAS  PubMed  Google Scholar 

  23. Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ (2012) Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) trial. Circulation 125:669–676

    Article  CAS  PubMed  Google Scholar 

  24. Larsen TB, Rasmussen LH, Skjoth F, Due KM, Callreus T, Rosenzweig M, Lip GY (2013) Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol 61:2264–2273

    Article  CAS  PubMed  Google Scholar 

  25. Dale B, Eikelboom JW, Weitz JI, Young E, Paikin JS, Coppens M, Whitlock RP, Connolly SJ, Ginsberg JS, Hirsh J (2013) Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction? J Thromb Thrombolysis 35:295–301

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Funding for this research was provided by Boehringer Ingelheim GmbH.

Author information

Authors and Affiliations

  1. The Heart Institute of Good Samaritan Hospital, 1225 Wilshire Blvd, Los Angeles, CA, 90017, USA

    Sharon L. Hale & Robert A. Kloner

  2. Division of Cardiovascular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

    Robert A. Kloner

Authors
  1. Sharon L. Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert A. Kloner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sharon L. Hale.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hale, S.L., Kloner, R.A. Dabigatran treatment: effects on infarct size and the no-reflow phenomenon in a model of acute myocardial ischemia/reperfusion. J Thromb Thrombolysis 39, 50–54 (2015). https://doi.org/10.1007/s11239-014-1098-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-014-1098-x

Keywords

Search

Navigation